Clinical trials: Investigation Time
Parkinson Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa…
- Trial name
- NCT07432958
- Testing
- AP-472
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Appello Pharmaceuticals, Inc.
Breast Implant; Complications, Infection or Inflammation
Histological Analysis of AlloMend® Acellular Dermal Matrix Used in Breast Implant Surgeries
This is a prospective, histologic analysis of biopsied tissue obtained from participants who have undergone a pre-pectoral breast reconstruction or augmentation surgery with expander placement and AlloMend® Acellular Dermal…
- Trial name
- NCT05744414
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AlloSource
Multiple Sclerosis
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South…
- Trial name
- CONTAIN (NCT01514370)
- Testing
- IFN beta 1a 44 mcg TIW, Curcumin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Erectile Dysfunction
A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation
The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to…
- Trial name
- NCT00210678
- Testing
- No intervention
- Volunteers
- 1,115 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pulmonary Disease, Chronic Obstructive
Study of GSK961081 in Healthy Volunteer Subjects
GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans.
- Trial name
- NCT00887406
- Testing
- GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Moderate-severe Glabellar Lines
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Evaluate onset time and safety of improvement effect of each group's forehead wrinkles after 2, 3, 4, 5, 14 days from administration of 20U dosage of DWP450-004 for adult patients who need more than moderate improvement of…
- Trial name
- NCT02568150
- Testing
- Single group, open-label
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Low Back Pain
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
This is a 6-month, nonrandomized, open-label extension study to assess the long-term safety of hydrocodone bitartrate extended-release (ER) tablets in patients with moderate to severe chronic low back pain who require continuous…
- Trial name
- NCT01922739
- Testing
- Hydrocodone ER
- Where
- 61 sites in United States
- Volunteers
- 182 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Breast Cancer
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions.
- Trial name
- NCT03697551
- Testing
- Satoreotide trizoxetan
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Ipsen
Infections, Rotavirus, Rotavirus Vaccines
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
GSK has submitted a registration file for its live attenuated oral human rotavirus (HRV) vaccine in several countries. In view of its registration in the Philippines, the present study will collect data on the safety of the…
- Trial name
- NCT00353366
- Testing
- Rotarix, Data collection
- Where
- 18 sites in Philippines
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Auscultation of Heart and Lungs
Pilot Study to Evaluate the Clinical Utility of Auscultation Software at Remote Locations
Primary Objective: Evaluation of the utility of real-time, scope-to-scope communication between commercially-available 3M Littmann Electronic Model 3200 Electronic stethoscopes over a dedicated intranet system for the assessment…
- Trial name
- NCT01138592
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Solventum US LLC
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg).
- Trial name
- NCT04345900
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 55 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Diabetes, Type 2 Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time.
- Trial name
- QWINT-2 (NCT05362058)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 113 sites in United States, Brazil and 9 more
- Volunteers
- 928 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
The purpose of this study is to investigate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06273340 for 14 days in healthy subjects of two age groups, aged 18-55 years (Group 1) and aged…
- Trial name
- NCT01934738
- Testing
- PF-06273340
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Anaemia
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease.
- Trial name
- NCT02689206
- Testing
- GSK1278863
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- GlaxoSmithKline
Parkinsonian Syndromes
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less…
- Trial name
- POET-2 (NCT00724906)
- Testing
- 123 I - ALTROPANE®
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Alseres Pharmaceuticals, Inc
Neutropenia, Breast Cancer
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when administered at varying intervals following Docetaxel and Cyclophosphamide…
- Trial name
- NCT04187898
- Testing
- Eflapegrastim, Docetaxel, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 59 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Hepatitis B, Hepatitis A
Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared
To evaluate the persistence of anti-hepatitis A virus (HAV) and anti-hepatitis B surface antigen (HBs) antibodies up to 2, 3, 4 and 5 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00197184
- Testing
- Twinrix™ Adult, Twinrix™ Junior
- Where
- 7 sites in Australia, Belgium and 1 more
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Pain
Elosan Efficacy Study (EES)
The "Elosan Cabin" is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage in patients with chronic pain, especially those with rheumatic diseases.
- Trial name
- NCT03823729
- Testing
- Elosan Cabin
- Where
- 3 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- Elosan AG